US › Healthcare

Nautilus Biotechnology Inc (NAUT)

US · Healthcare · Biotechnology

$0.99-2.45%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$190,000
Net profit
$-14.5M
Profit YoY
+3.8%
EPS
$-0.11
EPS estimate
$-0.14
Net margin
-7,615.3%

EPS came in at -0.11 against a street estimate of -0.14 — a beat of 21.4%.

Key statistics

Market cap
$124.3M
Forward P/E
0.0
P/B
0.95
Book value
$1.03
EPS (TTM)
$-0.45
52-week high
$4.31
52-week low
$0.62
50-day MA
$2.04
200-day MA
$2.23
Beta
0.81

Analyst view

Analysts rate Nautilus Biotechnology Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $4.00.

Shareholding

Insiders
33.16%
Institutions
41.03%

Largest institutional holders

FundStake
Perceptive Advisors LLC9.90%
Cercano Management LLC5.64%
Vanguard Capital Management, LLC2.00%
Hartland & Co1.83%
Comprehensive Financial Management LLC1.73%
Amazon.com Inc1.15%
Millennium Management LLC1.00%
Sentinel Trust CO Lba0.59%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nautilus Biotechnology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.